Current treatments focus on controlling inflammation and minimizing long-term damage. Learn more.

Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis, or AAV, causes inflammation of the blood vessels and can affect many parts of the body, including multiple organs. Because of this, ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for ...

-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- “The vasculitis community is elated that TAVNEOS is now approved, bringing a much-needed new treatment option to ...

Chronic lung disease is associated with a higher risk for infection in patients with ANCA-associated vasculitis during both induction and maintenance treatment.

Patients with a particular histopathologic phenotype may respond less well to rituximab, but it is still unclear what factors ...

Please provide your email address to receive an email when new articles are posted on . “Today is a momentous day in the history of ChemoCentryx; the culmination of decades of effort aimed at offering ...

Despite the frequency of coronary artery calcification among patients with antineutrophil cytoplasmic antibody-associated vasculitis, only 25% were using statins. A significant percentage of patients ...

Learn the difference between induction and maintenance phases in ANCA-associated vasculitis (AAV) treatment, including what to expect from medications like rituximab (Rituxan).

BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today ...

Patients who received plasmapheresis for ANCA-associated vasculitis vs those who did not were more likely to have had AKI, AKI requiring dialysis, hypoxia, and respiratory failure requiring mechanical ...

SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a ...